Inclusion Criteria:

- Histologic or cytologic confirmation of locally advanced or metastatic NSCLC
(IIIb-IV) at the time of original diagnosis.

- Completion of 4 cycles of chemotherapy of gemcitabine (1,000 or 1250mg/m^2/day on day
1 and 8) and cisplatin (70-80mg/m^2/day on day 1) every 3 weeks and have shown
response, Complete Response(CR), Partial Response (PR) or stable disease (SD) by
RECIST.

- WHO PS 0-1

- No prior radiotherapy to chest, immunotherapy or biologic therapy

Exclusion Criteria:

- Mixed small cell and non small-cell lung cancer history.

- Prior treatment with EGFR TKIs or VEGFR TKIs (prior treatment with cetuximab
[Erbitux] or bevacizumab [Avastin] is not permitted.)

- Evidence of severe or uncontrolled systemic disease or any concurrent condition which
in the investigator's opinion makes it undesirable for the patient to participate in
the study or which would jeopardize compliance with the protocol.

- Radiation therapy within 4 weeks before the start of study therapy. Major surgery
within 4 weeks, or incomplete healed surgical incision before starting study therapy.